Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Hepcidin predicts response to IV iron therapy in patients admitted to the intensive care unit: A nested cohort study

    Access Status
    Fulltext not available
    Authors
    Litton, E.
    Baker, S.
    Erber, W.
    Farmer, Shannon
    Ferrier, J.
    French, C.
    Gummer, J.
    Hawkins, D.
    Higgins, A.
    Hofmann, A.
    De Keulenaer, B.
    McMorrow, J.
    Olynyk, John
    Richards, T.
    Towler, S.
    Trengove, R.
    Webb, S.
    Chapman, A.
    Jenkinson, E.
    Palermo, A.
    Roberts, B.
    Date
    2018
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Litton, E. and Baker, S. and Erber, W. and Farmer, S. and Ferrier, J. and French, C. and Gummer, J. et al. 2018. Hepcidin predicts response to IV iron therapy in patients admitted to the intensive care unit: A nested cohort study. J Intensive Care. 6 (1).
    Source Title
    J Intensive Care
    DOI
    10.1186/s40560-018-0328-2
    ISSN
    2052-0492
    School
    Centre for Population Health Research
    URI
    http://hdl.handle.net/20.500.11937/72687
    Collection
    • Curtin Research Publications
    Abstract

    © 2018 The Author(s). Background: Both anaemia and red blood cell (RBC) transfusion are common and associated with adverse outcomes in patients admitted to the intensive care unit (ICU). The aim of this study was to determine whether serum hepcidin concentration, measured early after ICU admission in patients with anaemia, could identify a group in whom intravenous (IV) iron therapy decreased the subsequent RBC transfusion requirement. Methods: We conducted a prospective observational study nested within a multicenter randomized controlled trial (RCT) of IV iron versus placebo. The study was conducted in the ICUs of four tertiary hospitals in Perth, Western Australia. Critically ill patients with haemoglobin (Hb) of <100g/L and within 48h of admission to the ICU were eligible for participation after enrolment in the IRONMAN RCT. The response to IV iron therapy compared with placebo was assessed according to tertile of hepcidin concentration. Results: Hepcidin concentration was measured within 48h of ICU admission in 133 patients. For patients in the lower two tertiles of hepcidin concentration (<53.0µg), IV iron therapy compared with placebo was associated with a significant decrease in RBC transfusion requirement [risk ratio 0.48 (95% CI 0.26-0.85), p=0.013]. Conclusions: In critically ill patients with anaemia admitted to an ICU, baseline hepcidin concentration predicts RBC transfusion requirement and is able to identify a group of patients in whom IV iron compared with placebo is associated with a significant decrease in RBC transfusion requirement.

    Related items

    Showing items related by title, author, creator and subject.

    • Intravenous iron or placebo for anaemia in intensive care: the IRONMAN multicentre randomized blinded trial: A randomized trial of IV iron in critical illness
      The, I.; Litton, E.; Baker, S.; Erber, W.; Farmer, Shannon; Ferrier, J.; French, C.; Gummer, J.; Hawkins, D.; Higgins, A.; Hofmann, Axel; De Keulenaer, B.; McMorrow, J.; Olynyk, John; Richards, T.; Towler, S.; Trengove, R.; Webb, S.; The, A. (2016)
      Purpose: Both anaemia and allogenic red blood cell transfusion are common and potentially harmful in patients admitted to the intensive care unit. Whilst intravenous iron may decrease anaemia and RBC transfusion requirement, ...
    • The IRONMAN trial: a protocol for a multicentre randomised placebo-controlled trial of intravenous iron in intensive care unit patients with anaemia
      Litton, E.; Baker, S.; Erber, W.; French, C.; Ferrier, J.; Hawkins, D.; Higgins, A.; Hofmann, Axel; De Keulenaer, B.; Farmer, Shannon; McMorrow, J.; Olynyk, John; Richards, T.; Towler, Simon; Webb, S. (2014)
      Background: Allogeneic red blood cell (RBC) transfusion is associated with significant increases in mortality and major morbidity in patients admitted to the intensive care unit, and the blood supplies it requires are an ...
    • Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial
      Gummer, J.; Trengove, R.; Pascoe, E.; Badve, S.; Cass, A.; Clarke, P.; McDonald, S.; Morrish, A.; Pedagogos, E.; Perkovic, V.; Reidlinger, D.; Scaria, A.; Walker, R.; Vergara, L.; Hawley, C.; Johnson, D.; Olynyk, John; Ferrari, P. (2017)
      Background: Pentoxifylline has been shown to increase haemoglobin levels in patients with chronic kidney disease (CKD) and erythropoietin-stimulating agent (ESA)-hyporesponsive anaemia in the Handling Erythropoietin ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.